Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on the discovery and development of tumor-activated immuno-oncology therapies for the treatment of cancer. The firm uses its Geographically Precise Solutions (GPS) platform to develop tumor-activated molecules, including cytokines, antibodies and other biologics. The company was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Pharm.D.Dr. Rene Russo BCPS
CFO & COOMr. Christopher Frankenfield
Senior Vice President of Finance & AccountingMr. Kevin M. Brennan
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, alerts, and much more.